Ilkka Kantola
 Professor; Head of Medical Division, Turku university Hospital

Docent,  Faculty of Medicine (University of Turku) ilkkan@utu.fi : https://orcid.org/0000-0002-6228-522X CURRICULUM VITAE OF ILKKA KANTOLA041117.pdf

  

  

  

10 of 10

  

  

---

• Fabry disease: a review of current management strategies  (2010)  
  • QJM: An International Journal of Medicine
   Mehta A, Beck M, Eyskens F, Feliciani C, Kantola I, Ramaswami U, Rolfs A, Rivera A, Waldek S, Germain DP

  
  

• Metabolic syndrome; independent of its components; is a risk factor for stroke and death but not for coronary heart disease among hypertensive patients in the ASCOT-BPLA  (2010)  
  • Diabetes Care
   Gupta AK, Dahlof B, Sever PS, Poulter NR, ASCOT-BPLA Investigators, Kantola I

  
  

• Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial  (2010)  
  • Lancet
   Bakris GL, Sarafidis PA, Weir MR, Dahlöf B, Pitt B, Jamerson K, Velazquez EJ, Staikos-Byrne L, Kelly RY, Shi V, Chiang YT, Weber MA, ACCOMPLISH Trial Investigators, Kantola I

  
  

• The assessment of total cardiovascular risk in hypertensive subjects in primary care  (2010)  
  • Annals of Medicine
   Korhonen P, Vesalainen R, Aarnio P, Saaresranta T, Kautiainen H, Järvenpää S, Kantola I

  
  

• The choice of home bood pressure result reporting method is essential: Results mailed to physicians did not improve hypertension control compared with ordinary office-based blood pressure treatment  (2010)  
  • Blood Pressure
   Varis J, Kantola I

  
  

• The economic consequences of non-adherence to lipid-lowering therapy: results from the Anglo-Scandinavian-Cardiac Outcomes Trial  (2010)  
  • International Journal of Clinical Practice
   Lindgren P, Eriksson J, Buxton M, Kahan T, Poulter NR, Dahlöf B, Sever PS, Wedel H, Jönsson B, ASCOT Trial investigators, Kantola I

  
  

• Tromboosiprofylaksi suomalaisessa sairaalahoidossa  (2010)  
  • Lääkärilehti
   Virtanen L, Harjola V-P, Ahonen J, Kantola I, Rintala H, Lumio J, Kellokumpu I, Kankaanranta H, Härkki P, Miettinen H, Lassila R

  
  

• The effect of 12-month enzyme replacement therapy on myocardial perfusion in patients with Fabry disease  (2006)  
  • Journal of Inherited Metabolic Disease
   Kalliokoski RJ, Kantola I, Kalliokoski KK, Engblom E, Sundell J, Hannukainen JC, Janatuinen T, Raitakari OT, Knuuti J, Penttinen M, Viikari J, Nuutila P